stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
113.28
0.89
+0.79%
Follow BLLN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
|
+6 more TTM periods Free account |
0.00% | 0.00% | 23.27% | 0.00% | |
| 0.92% | 7.10% | 9.09% | 9.02% | ||
ROIC |
24.01% | 38.70% | 34.10% | 0.00% | |
Return on Tangible Assets |
0.55% | 4.22% | 5.35% | 7.57% | |
Average Days of Receivables |
49.79 | 63.11 | 68.79 | 73.76 | |
Free Cash Flow per Share |
0.99 | 0.57 | 0.71 | 0.72 | |
Free Cash Flow |
15.71 | 26.40 | 33.17 | 33.90 | |
Capital Expenditures |
(8.88) | (11.00) | (12.18) | (14.00) | |
| Other line items | |||||
Cash ROIC |
1.52% | 2.33% | 2.82% | 5.21% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 7.98 | 7.11 | |
Accounts Payable Turnover |
0.00 | 0.00 | 13.83 | 13.85 | |
Inventory Turnover |
0.00 | 0.00 | 7.65 | 6.36 | |
Average Days of Payables |
27.13 | 30.26 | 39.01 | 29.90 | |
Days of Inventory on Hand |
66.26 | 66.83 | 67.56 | 63.96 | |
Tax Rate |
(0.04) | (0.02) | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
16.19% | 15.13% | 14.90% | 15.22% | |
Selling, General and Administrative Expense of Revenue |
46.88% | 45.06% | 45.47% | 45.96% | |
Share Based Compensation of Revenue |
5.22% | 5.66% | 6.43% | 7.04% | |
Interest Coverage |
168.66 | 556.49 | 1,056.15 | 1,655.26 | |
Operating CF/Net income |
8.43 | 1.50 | 1.37 | 0.98 | |
Depreciation/Fixed assets |
0.58 | 0.53 | 0.49 | 0.00 | |
Capex/Depreciation |
(0.75) | (0.93) | (0.99) | 0.00 | |
Revenue per Share |
19.22 | 7.72 | 8.56 | 9.24 | |
Operating CF per Share |
1.55 | 0.81 | 0.98 | 1.01 | |
Capex per Share |
(0.56) | (0.24) | (0.26) | (0.30) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 4 Nov 2026